LXP5268 / LaunXP Biomedical - LARVOL DELTA

A proof-of-concept study of LXP5268 as an add-on neoadjuvant chemotherapy in patients with early-stage triple-negative breast cancer. (ASCO 2024) - "NACT consisted of docetaxel every 3 weeks for four cycles, followed by epirubicin plus cyclophosphamide every 3 weeks for an additional four cycles (24 weeks total). LXP5268 combined with NACT was more effective than NACT alone for early-stage TNBC, without increasing AEs. These results highlight LXP5268's potential in TNBC therapy. Previous studies indicated XIRP2 mutations in metastatic breast cancer."

Clinical • Breast Cancer • CNS Disorders • Constipation • Gastroenterology • Gastrointestinal Disorder • Hematological Disorders • Insomnia • Neutropenia • Oncology • Sleep Disorder • Solid Tumor • Triple Negative Breast Cancer • XIRP2